FibroGen (FGEN) Tops Q1 EPS by 9c, Revenues Miss

FibroGen (NASDAQ: FGEN) reported Q1 EPS of ($0.78), $0.09 better than the analyst estimate of ($0.87). Revenue for the quarter came in at $38.43 million versus the consensus estimate of $41.79 million.

“We are pleased at the continued adoption and growth of roxadustat in China,” said Enrique Conterno, Chief Executive Officer, FibroGen. “We are looking forward to the roxadustat FDA advisory committee meeting and the approval decision in Europe over the next few months, as well as advancing our late-stage pamrevlumab and roxadustat clinical programs, focused on areas of high unmet need.”

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• CMS Energy (CMS) Misses Q1 EPS by 1c ; Offers Guidance
• MarineMax (HZO) Misses Q2 EPS by 48c, provides guidance